Arrowhead Pharmaceuticals, Inc. $ARWR Shares Purchased by AlphaQuest LLC

AlphaQuest LLC increased its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 30,636.8% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 32,581 shares of the biotechnology company’s stock after purchasing an additional 32,475 shares during the quarter. AlphaQuest LLC’s holdings in Arrowhead Pharmaceuticals were worth $515,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ARWR. Vanguard Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 8.4% in the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock valued at $168,201,000 after buying an additional 1,018,273 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Arrowhead Pharmaceuticals by 138.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after buying an additional 2,774,933 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 0.9% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 2,528,982 shares of the biotechnology company’s stock valued at $32,220,000 after buying an additional 21,686 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Arrowhead Pharmaceuticals by 34.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,741,666 shares of the biotechnology company’s stock valued at $22,189,000 after buying an additional 447,456 shares during the period. Finally, Aberdeen Group plc raised its holdings in shares of Arrowhead Pharmaceuticals by 138.4% in the 1st quarter. Aberdeen Group plc now owns 1,072,827 shares of the biotechnology company’s stock valued at $13,668,000 after buying an additional 622,752 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Chardan Capital reiterated a “buy” rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a report on Monday, August 11th. B. Riley upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, August 11th. Wall Street Zen downgraded Arrowhead Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, July 18th. TD Cowen upgraded Arrowhead Pharmaceuticals to a “strong-buy” rating in a report on Monday, July 28th. Finally, Royal Bank Of Canada cut their price objective on Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an “outperform” rating on the stock in a report on Friday, August 8th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $43.14.

Insider Activity

In other news, insider James C. Hamilton sold 20,000 shares of the company’s stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $35.00, for a total transaction of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares of the company’s stock, valued at approximately $7,424,270. This represents a 8.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Over the last ninety days, insiders sold 60,000 shares of company stock worth $1,725,000. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $39.55 on Wednesday. The stock’s 50-day moving average is $31.37 and its two-hundred day moving average is $21.18. The company has a debt-to-equity ratio of 0.39, a current ratio of 4.87 and a quick ratio of 4.87. Arrowhead Pharmaceuticals, Inc. has a 1-year low of $9.57 and a 1-year high of $40.48. The company has a market cap of $5.47 billion, a price-to-earnings ratio of -30.90 and a beta of 1.13.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The firm had revenue of $27.77 million during the quarter, compared to analyst estimates of $29.01 million. During the same period in the prior year, the company posted ($1.38) earnings per share. Analysts forecast that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.